PROF Sanjoy Paul

PROF Sanjoy Paul


  • Research program in clinical & pharmaco-epidemiology



  • Professor Sanjoy Paul is an internationally recognised clinical trialist, biostatistician and a research administrator with long-standing experience in design and conduct of clinical trials and pharmaco-epidemiological studies in the fields of metabolic diseases. 

    Prof. Paul’s current role is Chair of Clinical Biostatistics, Epidemiology & Health Sciences Research, University of Melbourne, and Director of the Melbourne EpiCentre, a collaborative research centre embedded within the Royal Melbourne Hospital, Melbourne. 

    Prior to joining University of Melbourne Prof. Paul established the Clinical Trials and Biostatistics Centre at The University of Queensland (2009-13), and subsequently moved his research group to the QIMR Berghofer Medical Research Institute (2013-16). 

    Prior to moving to Australia in 2009, Prof. Paul created the Statistics & Modelling Group of the University of Oxford Centre for Diabetes, Endocrinology and Metabolism in the UK. Prof. Paul’s publication record includes articles in highly acclaimed research journals, including the New England Journal of Medicine (4 publications), Science Translational Medicine, Clinical Infectious Diseases, Diabetes, Diabetes Care, Diabetes Obesity & Metabolism, Cardiovascular Diabetology and Diabetologia, with total citations of 8,659 since 2011and M-Index of 1.8, having commenced his research career in 2004. 

    Prof. Paul is highly regarded for his strategic contributions in developing effective industry-academia research partnerships, and for playing pivotal roles in developing strategies to conduct clinical and pharmaco-epidemiological studies of high public health importance using real world data. He has been leading programme of studies in the fields of diabetes and cardiovascular diseases using big real-world primary care and ambulatory care databases from the UK and USA. The research programme covers three broad areas:   


Selected publications


Investigator on

Additional Grant Information


    Translating Health Discovery (THD) NCRIS Funding Program, 2013 ongoing

    Effect of weight change and its interactions with glycaemic control and blood pressure on cardiovascular and mortality risks in patients with type 2 diabetes. A Part of Programme of Clinical Epidemiological Studies. AstraZeneca Investigator Initiated Research Grant. 2016-2018. 

    Centre for Redefining antibiotic use to reduce resistance and prolong the lives of antibiotics (REDUCE). NHMRC CRE. 2016-2020. 

    Whole body vibration for osteoporosis: Shaking up our treatment options. NHMRC Project Grant. 2015-2019. 

    Evaluation of the association of old and new anti-diabetes drugs with the risk of heart failure in patients with type 2 diabetes. RBWH Foundation. 2016-2017. 

    Evaluation of the obesity paradox in diabetes: A longitudinal case-control study of half a million patients. NHMRC Project Grant. 2014-2017.
    Robust antibiotic dosing for critically ill patients receiving renal replacement therapy. NHMRC Project Grant. 2013-2016.

    Telehealth in residential aged care facilities: a pragmatic randomized control trial. NHMRC Project Grant (Gray L et al.) 2013-2017



Education and training

  • M.Sc, Gauhati Uiversity
  • PhD, Indian Statistical Institute
  • B.Sc, Gauhati Uiversity



Available for supervision

  • Y